Status:
COMPLETED
Iron Deficiency in Patients With Heart Failure and Reduced and Mildly Reduced Ejection Fraction
Lead Sponsor:
Jordan Collaborating Cardiology Group
Conditions:
Iron Deficiency
Heart Failure With Reduced Ejection Fraction
Eligibility:
All Genders
18+ years
Brief Summary
A significant percentage of patients with heart failure and reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF) have iron deficiency who are symptomatic. This is independent...
Detailed Description
The prevalence of chronic heart failure among the industrialized countries is 1-3%, and can exceed 30% in the elderly population. As the population ages, there is an increase in the number of co-morbi...
Eligibility Criteria
Inclusion
- Heart failure patients with ejection fraction \<59% (including those with with reduced ejection fraction of ≤40%, or mildly reduced EF (41-49%)) within the last 2 years.
- NYHA class II-IV.
- Able and willing to provide oral informed consent.
Exclusion
- Age\<18 years.
- Acute coronary syndrome.
- Known cases of iron overload (e.g. hemochromatosis); known cases of anemia due to other causes.
- Oral or intravenous iron supplements within the previous 3 months; erythropoietin stimulating agents or blood transfusion within the last 6 months.
- Active clinically relevant bleeding in the investigator's opinion.
- Patients with chronic inflammatory conditions (e.g. rheumatoid arthritis; Crohn's disease, etc.); active infection; and decompensated liver disease.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 22 2025
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT05992116
Start Date
September 1 2023
End Date
February 22 2025
Last Update
February 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abdali Hospital
Amman, Jordan, 11145